Zoetis reported a weak Q1 2026 as US companion animal sales fell 8% due to significant consumer price sensitivity, heightened competition, and lower veterinary clinic traffic. Management lowered full-year guidance and launched a cost-cutting program to navigate the challenging environment, while emphasizing the strength of its livestock business and upcoming pipeline. Global revenue was flat operationally, but excluding a $100M benefit from fiscal year alignment, it declined 5% operationally.
Zoetis reported a weak Q1 2026 as US companion animal sales fell 8% due to significant consumer price sensitivity, heightened competition, and lower veterinary clinic traffic. Management lowered full-year guidance and launched a cost-cutting program to navigate the challenging environment, while emphasizing the strength of its livestock business and upcoming pipeline. Global revenue was flat operationally, but excluding a $100M benefit from fiscal year alignment, it declined 5% operationally.
Management acknowledged significant headwinds from competition and consumer price sensitivity, revised guidance downward, and emphasized near-term corrective actions while expressing long-term confidence.
Reported gross margin was 71.66%, reinforcing the quarter's better-than-guided profitability.
U.S. pet health revenue declined 8% in Q1 due to price sensitivity and competition. Management acknowledged significant headwinds from competition and consumer price sensitivity, revised guidance downward, and emphasized near-term corrective actions while expressing long-term…
Zoetis lowered FY2026 revenue guidance to $9.68-$9.96B (2-5% growth) and adjusted EPS to $6.85-$7.00 to reflect the softer market.
U.S. pet health revenue declined 8% in Q1 due to price sensitivity and competition. Management acknowledged significant headwinds from competition and consumer price sensitivity, revised guidance downward, and emphasized near-term corrective actions while expressing long-term confidence.
Management acknowledged significant headwinds from competition and consumer price sensitivity, revised guidance downward, and emphasized near-term corrective actions while expressing long-term confidence.
“So distributors and retail partners took longer to work through their opening inventories and engaged in less replenishment activity.”
“Unlike prior competitive cycles, we do not currently have the benefit of underlying market expansion to cushion the revenue effect of competitive shareships”
“as well as a slowing of alternative channel sales, driven partly by script denials in retail.”
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| EPS | FY2026 | $6.85–$7.00below vs consensus | $6.92 | LOWERED |
| Revenue | FY2026 | $9.68B–$9.96Bbelow vs consensus | $9.82B | LOWERED |
The acquisition diversifies Zoetis into livestock genetics, a growing segment, and signifies they are deploying capital into new growth areas.
“we announced an agreement to acquire Neogen's animal genomics business, expanding our capabilities in livestock genetics.”
… Second, we're accelerating our science-to-scale model. shortening time from approval to launch, and translating that into growth. That includes prioritizing near-term launches and advancing convenience-led lifecycle innovation with our portfolio to create new ways to compete, including long-acting MABs, Percerta, and the recent Canadian approval of Convenia RTU, which expands access to a ready-to-use, cost-effective formulation. Third, We announced an agreement to acquire Neogen's animal genomics business, expanding our capabilities in livestock genetics. This reflects our broader approach to targeted business development, where we continue to be strategic in pursuing opportunities to unlock new sources of growth over time. Finally, we are sharpening our approach to capital allocation while continuing to invest in our key growth priorities. As reflected in our adjusted net income, we acted decisively as growth softened in the quarter and launched a comprehensive cost and productivity program, further tightening discretionary spending, driving procurement and operating efficiencies, and assessing organizational levers to deliver a leveraged P&L in 2026 and beyond. We …